Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHMST3)

• Drug Name: CCX915 Drug Info
• Synonyms: Meglitinide; 54870-28-9; Meglitinide [INN]; Meglitinidum [INN-Latin]; Meglitinido [INN-Spanish]; HB 699; UNII-8V6OK1I088; BRN 2817215; 8V6OK1I088; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)benzoic acid; 4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)benzoasaeure [German]; p-(2-(5-Chloro-o-anisamido)ethyl)benzoic acid; C17H16ClNO4; 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid; Meglitinido; Meglitinidum; Benzoic acid, 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 41214
  CAS Number: CAS 54870-28-9
  TTD Drug ID: DMHMST3

Molecule-Related Drug Atlas

Drug(s) Targeting ATP-binding cassette transporter C9 (ABCC9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[4]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[5]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[6]
Nicorandil	DMIYJFV	Angina pectoris	BA40	Approved	[7]
BTS-67582	DM54K2P	Diabetic complication	5A2Y	Discontinued in Phase 2	[8]
KRN-2391	DMZ1SEW	Angina pectoris	BA40	Discontinued in Phase 2	[9]
BMS-191095	DMKFXTD	Angina pectoris	BA40	Discontinued in Phase 1	[10]

Drug(s) Targeting C-C chemokine receptor type 2 (CCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cenicriviroc	DM4V8WF	Human immunodeficiency virus infection	1C62	Phase 2	[11]
MLN1202	DM24SOL	Metastatic cancer	2D50-2E2Z	Phase 2	[12]
BMS-813160	DMKY638	Diabetic nephropathy	GB61.Z	Phase 2	[13]
CCX-140	DMJ9XCO	Diabetic nephropathy	GB61.Z	Phase 2	[14]
AZD-2423	DMF34UY	Chronic obstructive pulmonary disease	CA22	Phase 2	[15]
CCX872	DMPVAUT	Pancreatic tumour	2C10	Phase 2	[16]
MK-0812	DMRT8K4	Multiple sclerosis	8A40	Phase 2	[17]
Aminoguanidine	DMJQDUC	Diabetic retinopathy	9B71.0	Phase 1	[18]
TAK-202	DMVYEFZ	Melanoma	2C30	Phase 1	[19]
OPL-CCL2-LPM	DM3HOUX	Arthritis	FA20	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-binding cassette transporter C9 (ABCC9)	TTEF5MJ	ABCC9_HUMAN	Blocker	[2]
C-C chemokine receptor type 2 (CCR2)	TTFZYTO	CCR2_HUMAN	Antagonist	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035649)
• [2] Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol. 2003 Feb 15;547(Pt 1):159-68.
• [3] Marketed and experimental medicines for the treatment of multiple sclerosis. The Association of the British Pharmaceutical Industry. 2009.
• [4] Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90.
• [5] Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
• [6] Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
• [7] A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6.
• [8] BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9.
• [9] Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes
• [10] The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats.J Cereb Blood Flow Metab.2007 Feb;27(2):348-55.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [13] A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
• [14] Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
• [15] CA patent application no. 841416, Method of selecting therapeutic indications.
• [16] Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
• [17] Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
• [18] Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.